Investigating the candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: immunology of glycoconjugates with high carbohydrate loading
We investigated the immune responses of rabbits that were immunised with lipopolysaccharide (LPS)-based glycoconjugates by measuring the reactivity of the derived sera to a panel of selected wild-type and mutant strains of Neisseria meningitidis. In all cases, high titers of antibodies capable of recognising LPS elaborating the identical structure as presented on the immunising glycoconjugate were obtained, and in most cases the derived sera also recognised heterologous strains including wild-type, but at lower titers. However, although serum bactericidal antibodies were consistently obtained against strains elaborating the same LPS structure as the immunising antigen, this functional response was not observed against wild-type strains. We identified several potentially competing neo-epitopes that had been introduced via our conjugation strategies, which might compete with the conserved inner core oligosaccharide target region, thus reducing the antibody titers to epitopes which could facilitate bactericidal killing. This study has therefore identified key factors that are crucial to control in order to increase the likelihood of obtaining bactericidal antibodies to wild-type meningococcal cells with LPS-derived glycoconjugates. Glycoconjugates utilised in this study, have been found to contain epitopes that do not contribute to the derivation of antibodies that may facilitate bactericidal killing of wild-type strains and must be avoided in future LPS-based glycoconjugate preparations.
KeywordsNeisseria meningitidis Conjugate vaccine LPS
We thank Perry Fleming (core Bacterial Culture Facility) for large scale biomass production, Jacek Stupak for recording CE-ES-MS and the NRC-IBS animal facility for animal care. This work was supported by Novartis Vaccines. We thank Drs. Paolo Costantino and Francesco Berti for helpful discussions.
- 2.Gidney, M.A.J., Plested, J.S., Lacelle, S., Coull, P.A., Wright, J.C., Makepeace, K., et al.: Development, characterisation and functional activity of a panel of specific monoclonal antibodies to inner core lipopolysaccharide (LPS) epitopes in Neisseria meningitidis. Infect. Immun. 72, 559–569 (2004)CrossRefPubMedGoogle Scholar
- 3.Plested, J.S., Harris, S.L., Wright, J.C., Coull, P.A., Makepeace, K., Gidney, M.A.J., et al.: Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremia. J. Infect. Dis. 187, 1223–1234 (2003)CrossRefPubMedGoogle Scholar
- 4.Cox, A.D., Zou, W., Gidney, M.A.J., Lacelle, S., Plested, J.S., Makepeace, K., et al.: Candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: developmental chemistry and investigation of immunological responses following immunization of mice and rabbits. Vaccine 23, 5045–5054 (2005)CrossRefPubMedGoogle Scholar
- 5.Cox, A.D., St. Michael, F., Neelamegan, D., Lacelle, S., Cairns, C.M., Richards, J.C.: Investigating the candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: chemical strategies to prepare glycoconjugates with good carbohydrate loading. Glycoconjugate J. 27, 401–417 (2010)CrossRefGoogle Scholar
- 13.Torano, G., Toledo, M.E., Baly, A., Fernandez-Santana, V., Rodriguez, F., Alvarez, Y., et al.: Phase I clinical evaluation of a synthetic oligosaccharide-protein conjugate vaccine against Haemophilus influenzae type B in human adult volunteers. Clin. Vaccine. Immunol. 13, 1052–1056 (2006)CrossRefPubMedGoogle Scholar